Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
butorphanol + dexmedetomidine
- Development stage
- Phase 4
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
A combination medication consisting of butorphanol, a synthetic opioid agonist-antagonist analgesic, and dexmedetomidine, an α2-adrenoceptor agonist. This combination provides synergistic sedative and analgesic effects, making it useful for procedures requiring moderate to deep sedation and pain control. In human medicine, it's used for procedures like burn dressing changes and microvascular decompression surgeries, while in veterinary medicine it's commonly used for sedation and minor surgical procedures in various species.
- Other names
- dexmedetomidine and butorphanolDex-But
02
Targets
ADRA2A (α2A)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on butorphanol + dexmedetomidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on butorphanol + dexmedetomidine.